Kornimate/medical-research-clean huggingface dataset:
effect of lactobacillus paracasei ps23 on improving aging and muscle loss in the elderly

Conditions: Elderly; Muscle Loss; Depression; Anxiety

Summary: this study refers to the supplementation of ps23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people.

taiwan has become an aging society in recent years. there are important issues to attenuate aging and activate the potential capacity of elderly population. the physical function of middle-aged and older people will degenerate with age and produce age-related diseases. common symptoms are organ function deterioration, and old age disability caused by malnutrition and muscle loss is also a common care problem. therefore, how to prevent the complications of muscle loss is one of the important ten years of geriatric research. although past research has been confirmed, it can improve the debilitating condition of the elderly through nutrition counseling and exercise intervention. however, there is not much in-depth discussion on how probiotics can improve muscle loss and delay symptoms in elderly people. therefore, this study refers to the supplementation of ps23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people. one hundred and twenty elderly people will be recruited and then divided into three groups with 40 people in each group: (a) placebo group, (b) ps23 probiotic group, (c) ps23-ht prebiotic group, supplemented for 12 weeks. the diet record, functional test and muscle mass will be carried out every six weeks after the start, to understand whether ps23 is effective in improving muscle loss and weakness in elderly people.

Eligibility criteria:
inclusion criteria: * age between 65 and 85 years old exclusion criteria: * have taken antibiotics within one month or are receiving antibiotic treatment * have used probiotic products in powder, capsule or tablet form within two weeks (except for yogurt, yogurt, yakut and other related foods) * people allergic to lactic acid bacteria products * patients diagnosed with stroke or hypertension (systolic blood pressure greater than 139, diastolic blood pressure greater than 89) * exclusion of limbs and hips that have been replaced with artificial joints * persons with incapacity/insufficient decision-making ability * who has been determines that it is not suitable to participate in the research.
point of care ultrasound for diagnosis of abdominal free air

Conditions: Free Air in Abdomen

Summary: this study evaluates the ability of ultrasound to identify intraperitoneal free air. the study will consist of blinded review of abdominal ultrasound images of patients before and after laparoscopic surgery, a procedure which results in the introduction of air into the peritoneal cavity.

free peritoneal air is a marker of potential intraabdominal catastrophe, reflecting perforation of a hollow viscous organ such as stomach or intestine. while definitively identified by computed tomography, this diagnostic test can be delayed. presence of air beneath the diaphragm on an upright chest or abdominal radiograph can allow for faster diagnosis, but again can present limitations in terms of timing. bedside clinician performed ultrasound has become standard practice in emergency medicine and critical care settings. traditionally, air is not conducive to diagnostic ultrasound, but the artifacts it creates can be used to give clues about certain conditions. recently this artifact has been proposed as a means to identify free peritoneal air. several small studies have shown promise for the technique, but further investigation is warranted. in this study the investigators will generate a database of standardized abdominal ultrasound images in subjects undergoing laparoscopic surgery. during this surgery, the peritoneal cavity is intentionally insufflated with air. the majority of this is removed at the end of the case, but small volumes of air remain, as evidence by the presence of air on ct scan when performed shortly after surgery. the investigators will obtain a standardized set of images preoperatively and post operatively which will then be reviewed in a blinded fashion by three expert reviewers, one each from radiology, surgery and emergency medicine, with data analysis to determine sensitivity and specificity of ultrasound for free air.

Eligibility criteria:
inclusion criteria: * subjects scheduled for elective laparoscopic surgery * age 18 or greater exclusion criteria: * age less than 18 * pregnant * unable to provide consent

Keywords: laparoscopic surgery transabdominal ultrasound free air
a retrospective study in patients with mild to moderate covid-19

Conditions: COVID-19

Summary: the purpose of this retrospective study is to analyze real-world disease progression in mild-moderate covid-19 patients with at least one risk factor for serve covid-19 illness or death.

this study is a retrospective, real world study, without any intervention in clinical diagnosis and treatment, and only real world data are collected for analysis. the investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. the study will collect and analyze available symptoms, risk factors and sars-cov-2 ct value up to 28 days.

Eligibility criteria:
inclusion criteria: * participants who have a positive sars-cov-2 test result. * participants who have one or more mild or moderate covid-19 symptoms. * participants who have one or more of the following requirements: ≤7 days from the first positive test for sars-cov-2 virus infection to day 1; ≤5 days from the first onset of covid-19 symptoms to day 1. * participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death. exclusion criteria: * participants who are diagnosed with severe/critical covid-19 before day 1. * participants who have spo2≤93% on room air at sea level or pao2/fio2≤ 300, or respiratory rate ≥30 per minute before day 1. * participants who have received mechanical ventilation before day 1. * participants who have received or plan to receive a sars-cov-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) before and during hospitalization. * participants who have received convalescent covid-19 plasma treatment before and during hospitalization.

Keywords: mild to moderate covid-19
association between cardiopulmonary function and plantar pressure in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: it aims to understand the differences in everyday mobility and activity capabilities among patients with varying disease progression and severity, to serve as reference indicators for evaluating the effectiveness of pulmonary rehabilitation exercise training.

background： chronic respiratory diseases and chronic obstructive pulmonary disease (copd) are major causes of chronic illness and death worldwide. patients with chronic respiratory diseases experience muscle weakness and respiratory difficulties, leading to restricted physical activity, decreased functional capacity, exercise intolerance, and limb muscle atrophy. while exercise training can effectively improve limb strength, there is a lack of objective data exploring different disease progressions and clinical cardiopulmonary limitations, hence this study utilizes plantar pressure distribution to research lower limb strength and cardiopulmonary function in patients, hoping to identify relevant indicators for necessary exercise training. methods： the study plans to enroll 60 participants, divided into two groups (30 in the control group and 30 in the case group) matched 1:1. the study will be conducted at the pulmonary rehabilitation therapy room on the sixth floor of fu-jen catholic university hospital. in addition to basic demographic and clinical physiological parameters, all participants will undergo the 6-minute walk test, the timed up and go test, simple pulmonary function tests, body composition analysis, and statistical analysis. effect： the trial is expected to effectively determine which patients require exercise training based on the correlation between plantar pressure analysis and results from the 6-minute walk test and timed up and go test. these results are anticipated to correlate positively with disease severity.

Eligibility criteria:
inclusion criteria: * age between 45 and 65 years * patients with chronic respiratory diseases requiring pulmonary rehabilitation * signed informed consent form exclusion criteria: * current tracheostomy * home use of oxygen therapy or ventilators * diagnosed with severe left heart failure (nyha iii-iv) * patients diagnosed with neuromuscular diseases * had an acute exacerbation of copd in the past three months * unable to perform cardiopulmonary exercise testing

Keywords: chronic obstructive pulmonary disease plantar pressure pulmonary rehabilitation 6-minute walk test
an intervention on psychosocial health in women with unsuccessful ivf experience

Conditions: Infertility; Failed in Vitro Fertilisation

Summary: the goal of this interventional study is to learn if web-based support program can improve the psychosocial health status in women with unsuccessful ivf experience. the main questions it aims to answer are: does web-based support decrease the depressive symptoms, anxiety and infertility-related stress? does web-based support decrease the hopelessness? does web-based support increase the coping skills with infertility-related stress? researchers will compare this intervention to a control group to see if web-based support program improves psychosocial health. participants will: use the web-based support intervention for 5 weeks or have no intervention. complete the surveys on the website before and after the intervention.


Eligibility criteria:
inclusion criteria: 1. having at least three repeated unsuccessful ivf experiences, 2. maximum one month has passed since the negative ivf experience, 3. participating in the study voluntarily, 4. being able to read, understand and communicate in turkish. exclusion criteria 1. not having access to the internet/not knowing how to use it, 2. having any psychiatric disease/being in the 'severe depression' grade as a result of the beck depression inventory, 3. having at least one living child. exclusion criteria from the study in the stages after including the study: 1. spontaneous pregnancy occurring, 2. starting a new treatment cycle, 3. not continuing to monitor the modules on the website.

Keywords: infertility web-based support psychosocial health
disposition of intravenous ketorolac

Conditions: Postoperative Pain

Summary: the purpose of this study is: * to document ketorolac disposition (concentration/time profile, protein binding, metabolism) and its covariates following intravenous (iv) administration of ketorolac right after caesarean section and to compare those observations (n=32) with non-pregnant state (n=8) (intra-subject pk comparison) * to document biochemical tolerance of ketorolac * to evaluate if optimalisation of ketorolac dose regimen during pregnancy and labor are appropriated and needed * to quantify the neonatal exposure to ketorolac through excretion in the breast milk

prospective, single-center, open label study on the pharmacokinetics of intravenous (iv) ketorolac administration in pregnant women right after caesarean section. patients will be included after signed informed consent. ketorolac has been selected for this study as it is routinely administered for postoperative pain relief. at this stage, we only have the intention to document ketorolac pharmacokinetics and metabolism based on the dosing regimen as currently used in the clinical setting, and therefore will not interfere with either clinical indications, nor with dosing as prescribed by the attending physician. this drug is routinely administered (30 mg q8h) after caesarean section. drug administration and collection of samples will be obtained to the current clinical and nursing standard procedures. after dilution in 50-100 ml bag of normal saline drug will be administered after caesarean section by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. the intended duration of administration is 5-10 minutes. blood samples will be collected (in heparinised tubes) according to following schedule: 1, 2, 3, 4, 6 and 8 hours after iv administration, through a second peripherally inserted venous catheter dedicated for blood sampling only. blood samples will be centrifuged immediately after collection and subsequently stored at -20 °c until analysis. urine samples will also be collected, before drug administration in the first 8 hours after the first drug administration, through a bladder catheter in patients in whom a bladder catheter is available for clinical indications. in a subgroup of former patients (n=8), we plan to repeat this procedure 6-12 weeks after delivery (for intra-subject pk comparison). however, only a single iv ketorolac dose will be administered, and sampling will be limited to 6 samples up to 8 h following start of iv administration. a population pharmacokinetics approach will be used, hereby comparing the data on pk already reported in adults and the newly collected data following pregnancy.

Eligibility criteria:
inclusion criteria: * signed informed written consent * pregnant women to whom ketorolac is administered by intravenous route for clinical indications * preferable availability for revision in 6-12 weeks after delivery (around routine post-delivery check-up). exclusion criteria: * withdrawal of informed written consent * known nsaid's intolerance

Keywords: ketorolac pain pregnancy non-pregnant state
mitral valve area assessment: comparison with transthoracic echocardiography and magnetic resonance imaging

Conditions: Mitral Valve Stenosis

Summary: to compare mitral valve area in rheumatic mitral valve stenosis with cardiac magnetic resonance imaging and conventional transthoracic echocardiography.

clinical assessment of severity of mitral stenosis depends on both the presence of symptoms and mitral valve area . evaluation of mitral valve area with transthoracic echocardiography maintains rapid, accurate analysis of valve disease and serves as a practical gold standard for clinical evaluation. cardiac magnetic resonance imaging (cmri) is a recently used method that allows to evaluate cardiac structures and function noninvasively. direct visualization of valve area with cmri is also possible and it has been shown that the valve area assessed by cmri planimetry correlates reliably with the invasive assessment. velocity-encoded cardiac magnetic resonance imaging can be used to quantify mitral valve area. the objective of this study was to evaluate mitral valve area with cmri and compare it with echocardiographic methods including 2d planimetry, doppler continuation equation and doppler pressure half-time

Eligibility criteria:
inclusion criteria: * rheumatic mitral valve stenosis exclusion criteria: * degenerative mitral valve disease * ef\<50% * atrial fibrillation * inconclusive planimetric assessment * moderate or severe mitral regurgitation * moderate or severe aortic regurgitation * history of previous mitral valve commissurotomy or balloon valvotomy

Keywords: magnetic resonance imaging, mitral valve area
study of low field magnetic stimulation (lfms) on measures of sleep

Conditions: Insomnia, Primary

Summary: participants will be recruited and screened through ongoing studies in the sleep and anxiety disorders clinic. participants with insomnia will be consented to complete several questionnaires, undergo a brief physical exam, provide a urinalysis, and undergo 5 nights of active or sham low field magnetic stimulation (lfms) followed by an overnight sleep study. each of the two treatment conditions (active versus sham) will be conducted on two consecutive nights. there will be no more than 7 days between the adaptation night and the first treatment condition and no more than 7 nights between each of the two-night treatment conditions . thus, each participant who completes the full study will spend a total of 5 nights in the sleep laboratory and the time interval from the first adaptation night to completion of the study may range from 5-19 days for any particular individual.


Eligibility criteria:
inclusion criteria: * insomnia diagnosis per dsm-5 criteria * performing tasks in a timely manner (compared to the person's usual level of performance) * pittsburgh sleep quality index (psqi) \> 6 and one of the following: * sleep efficiency \< 85% (per consensus sleep diary) * insomnia severity index (isi) score \> 15 * sleep latency (subjective) and/or time awake after sleep onset (subjective) \>30 minutes. * not currently depressed (previous major depressive episodes and current antidepressant medication permitted as long as remission and current medication dosage has been stable for ≥ 1 month). * willing to refrain from alcohol for twenty-four hours before presenting to sleep lab for sleep studies * bmi \> 18 and \< 50 kg/m2 exclusion criteria: * current major depressive episode * current substance-induced depressive disorder * self-reported use of benzodiazepines or hypnotic drugs in last two weeks * self-reported use of marijuana in previous 72 hours * alcohol use disorders identification test (audit) score \> 10 * fagerstrom test for nicotine dependence (ftnd) score \> 4 * insomnia limited to early morning awakening (without difficulty initiating or maintaining sleep), * narcolepsy * seizure disorder (not including childhood febrile seizures) * recent treatment with anticonvulsant medications * obstructive or central sleep apnea * circadian rhythm sleep-wake disorders * recurrent isolated sleep paralysis * current substance-induced insomnia * chronic pain disorder * daily caffeine consumption \> 500 mg/d (uhde, 1989) * restless legs syndrome * periodic leg movement disorder * benzodiazepines or antipsychotic medications during past 30 days * presence of drugs of abuse (excluding marijuana, urinalysis) * pregnancy or plans to become pregnant * history of severe allergic reactions to adhesive tape * history of neurological disorder * conductive, ferromagnetic or other magnetic-sensitive metals in the head, neck, chest, upper arms, or any area that will be within 18 inches of the treatment coil.
transseptal vs retrograde aortic ventricular entry to reduce systemic emboli

Conditions: Neurocognitive Dysfunction

Summary: this study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (vt) and/or premature ventricular contractions (pvcs).

this study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (vt) and/or premature ventricular contractions (pvcs). participants will be followed for 6 months post-study procedure. this study will be conducted at up to 12 clinical sites in the united states. a total of one-hundred and fifty (150) participants will be enrolled and randomized.

Eligibility criteria:
inclusion criteria: 1. men and women ≥ 18 years of age 2. planned/scheduled endocardial ventricular tachycardia (vt) or premature ventricular contraction (pvc) catheter ablation procedure 3. for this patient, the current plan of the operator must be to pursue a catheter ablation target in the left ventricular endocardium that can be accessed by either a transseptal puncture or retrograde aortic approach 4. life expectancy of at least 1 year 5. willing and able to undergo pre- and post-ablation mris 6. willing and able to return and comply with scheduled follow up visits (through the 6 month follow-up) 7. willing and able to provide written informed consent exclusion criteria: 1. planned epicardial ablation that would include a coronary angiogram (during the index ventricular tachycardia (vt) or premature ventricular contraction (pvc) catheter ablation procedure) 2. any contraindication to mri (as defined by the institution performing the mri) 3. clinical contraindication to a retrograde aortic approach as determined by the treating physician, including: 1. severe aortic stenosis 2. mechanical aortic valve 4. clinical contraindication to a transseptal puncture as determined by the treating physician, including: 1. severe mitral valve stenosis 2. mechanical mitral valve 3. atrial septal defect (asd) or patent foramen ovale (pfo) closure device that would preclude a transseptal puncture 4. mitraclip or alfieri mitral valve repair that would preclude a transseptal puncture 5. planned or known need to perform either a retrograde aortic approach or transseptal approach (such as to target another site during the same procedure) 6. inability to speak, read, and write in the english language at a 6th grade level (required for the neurocognitive function testing) 7. current mental impairment or other diagnosis which precludes accurate assessment of neurocognitive function or which may not allow patient to understand the nature, significance and scope of the study 8. inability to perform neurocognitive function testing after \> 24 hours free of sedating medications
intravenous sodium thiosulfate on coronary calcification in patients on hemodialysis

Conditions: Coronary Calcification; Vascular Calcification

Summary: the present study will examine the treatment effect of sodium thiosulfate on coronary calcification in patients on hemodialysis.

coronary calcification (cac) is prevalent among patients with end-stage renal disease (esrd). high serum phosphate, the intake of calcium containing phosphate binder as well as dialysis vintage have been shown to be associated with the increasing prevalence of cac. high cac score examined by electron-beam ct scan or multi-slice ct scan associates with an increased cardiovascular mortality in esrd. in series of case reports, intravenous sodium thiosulfate (sts) reduced the calcium burden in calcific uremic arteriopathy and soft tissue calcification. this was believed to be due to the calcium chelation effect of sts.

Eligibility criteria:
inclusion criteria: * cac score \> 300 * life expectancy \> 6 months * dialysis vintage \> 6 months exclusion criteria: * non-compliance to hemodialysis

Keywords: coronary calcification vascular calcification sodium thiosulfate